close

Covid-19 pandemic: Kodak stock surges 655% on drug production news

The company's value climbed to $1.99 billion as of 10:25 am in New York, after closing on Friday shy of $100 million

Bloomberg
Stock markets, Shares
Premium

Kodak shares tripled on Tuesday on news of a $765 million loan to shift part of its factories to produce drug ingredients

Shares of Eastman Kodak have leapt 2,441 per cent higher this week, sending its market valuation to nearly $2 billion, after it won a government loan to help produce ingredients used in key generic medicines to fight the coronavirus. 
Kodak, the storied photography giant whose business and shares were devastated by the switch to filmless cameras, gained as much as 655 per cent on Wednesday, triggering at least six halts for volatility along the way. More than 110 million shares traded hands, more than 23 times its typical volume. 
The company’s value climbed to $1.99 billion as of 10:25 am in New York, after closing on Friday shy of $100 million.
Or

Also Read

Kodak CA 55-inch 4K UHD TV review: Minimally designed, offers more in less

Lockdown 2.0 guidelines: India Inc buckles up to deliver after reboot bid

Coronavirus outbreak: Stock exchanges activate disaster recovery sites

Markets shed Covid-19 pessimism with biggest single-day gain since 2009

Adani Green surges 5%, hits record high on no material impact of Covid-19

Wall Street adds to gains after Fed pledges more support to US economy

Oil gains on sharp US crude inventory drop; Covid-19 keeps surge in check

Wall Street rises on upbeat earnings as Fed looms; Nasdaq up over 1%

How Covid-19's crippling effects are crushing govt funds, credit ratings

Southeast Asian IPOs show tentative revival as issuers brave markets

First Published: Jul 30 2020 | 3:32 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to read more on Business-Standard.com